Terminated PHASE3 INTERVENTIONAL 2-arm NCT00557921

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) (COGENT-1)

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

Sponsor: Cogentus Pharmaceuticals

Conditions Acute Coronary Syndrome Coronary Artery Disease Myocardial Infarction Percutaneous Coronary Intervention

Interventions CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin Plavix (clopidogrel 75 mg) and aspirin

Updated 7 times since 2017 Last updated: Jan 27, 2009 Started: Dec 31, 2007 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated by Sponsor

Other Acute Coronary Syndrome trials with similar outcome

Browse all Acute Coronary Syndrome trials

Listed as NCT00557921, this PHASE3 trial focuses on Acute Coronary Syndrome and Coronary Artery Disease and remains terminated or withdrawn. Sponsored by Cogentus Pharmaceuticals, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cogentus Pharmaceuticals

Data source: Cogentus Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Aguascalientes, Mexico , Albany, United States , Albi, France , Alexander City, United States , Anaheim, United States , Anderson, United States , Antofagasta, Chile , Arlington, United States , Asheville, United States and 387 more locations